BioWorld MedTech

Nov. 29, 2016

TAVR pioneer Edwards enters TMVR market with Valtech Cardio acquisition

Edwards Lifesciences Corp. has agreed to acquire Or Yehuda, Israel-based Valtech Cardio Ltd. for $340 million, with the potential for $350 million in additional milestone payments. Read More

Revised Cures bill, minus mandatory NIH funding, heads for 2nd House vote

GE and Boston Children's collaboration targets childhood brain diseases

FDA adds details to performance tests in endoscope safety final

Single patent system to be ratified by U.K.

Daily M&A

Financings

Other news to note

Regulatory front

Product briefs

MDD's Cardiology Extra

Today's news in brief

BioWorld

BioWorld briefs for Feb. 11, 2025.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...